Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

USB Piper Downgrades Genzyme

USB Piper Jaffray downgrades Genzyme (GENZ) shares to market perform from outperform.

Analyst Mark Augustine says after a strong stock performance in 2000-2001, he sees 2002 as a more challenging year. Although he continues to expect strong Renagel sales growth, he believes the peak sales potential lies closer to $500 million than the $1 billion forecast offered by the company.

He views Vevesca's U.S. approval prospects as a coin toss at best. An early take on the company's Fabrazyme competitive situation in Europe is that market share favors TBIO's Replagal, which could put assumptions in Genzyme's EPS at risk.

blog comments powered by Disqus